Drug Resistance Research for Osteosarcoma

Age: Any Age

Sex: Any

Trial Phase: Academic

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

763 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this study is to investigate tumors in the laboratory to determine how and why they respond, or fail to respond to different drug therapies. This study will also investigate why high pressure develops within tumors and how this affects how well drugs work. We will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of osteogenic sarcoma and other solid tumors.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What safety data exists for the treatment being studied in the osteosarcoma drug resistance research?

The research articles focus on developing models to study drug resistance in osteosarcoma, but they do not provide specific safety data for the treatment in humans. ^{1 2 3 4 5}

How does this drug differ from other treatments for osteosarcoma?

This drug research focuses on overcoming resistance to standard MAP chemotherapy (methotrexate, adriamycin, and cisplatin) in osteosarcoma by using patient-derived xenografts (PDX) and in vitro models to better understand and target resistance mechanisms, which is a novel approach compared to traditional treatments. ^{2 3 4 6 7}

Research Team

John Healey, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for individuals with a presumed or confirmed diagnosis of bone cancer (osteosarcoma) or other solid tumors who are undergoing biopsy or surgery. It's open to adults and minors; adults must consent, while minors give assent and have parental consent.

Inclusion Criteria

I have or had a biopsy or surgery for bone or solid tumor cancer diagnosis or treatment.

I am 18 or older and have signed a consent form.

I am under 18 and both I and my guardian have agreed to the treatment.

Exclusion Criteria

N/A

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Sample Collection

Tumor and blood samples are collected for laboratory analysis to study chemotherapy resistance and oncogenesis

1 week

1 visit (in-person)

Laboratory Analysis

Tumor samples are analyzed in vitro to determine chemotherapy resistance and correlate with clinical outcomes

4-6 weeks

Follow-up

Participants are monitored for safety and effectiveness after sample collection and analysis

4 weeks

Treatment Details

Interventions

• NA
• Tissue Procurement

Trial Overview The study aims to understand how osteogenic sarcoma and other solid tumors react to drug therapies by examining tumor tissue and blood samples. Researchers will look into why some tumors resist treatment and the impact of internal tumor pressure on drug effectiveness.

Participant Groups

Group I: 1 Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

Hospital for Special Surgery, New York

Collaborator

Trials

257

Recruited

61,800+

Weill Medical College of Cornell University

Collaborator

Trials

1,103

Recruited

1,157,000+

Columbia University

Collaborator

Trials

1,529

Recruited

2,832,000+

Rockefeller University

Collaborator

Trials

162

Recruited

16,700+

References

1. Switzerland pubmed.ncbi.nlm.nih.gov

Challenges of Systemic Therapy Investigations for Bone Sarcomas. [2022]

2. England pubmed.ncbi.nlm.nih.gov

The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review. [2023]

3. Switzerland pubmed.ncbi.nlm.nih.gov

In-Vitro and In-Vivo Establishment and Characterization of Bioluminescent Orthotopic Chemotherapy-Resistant Human Osteosarcoma Models in NSG Mice. [2020]

4. Switzerland pubmed.ncbi.nlm.nih.gov

Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation. [2021]

6. China pubmed.ncbi.nlm.nih.gov

[Establishment of a cisplatin-multidrug resistance cell line of human osteosarcoma]. [2015]

7. United States pubmed.ncbi.nlm.nih.gov

In vitro chemosensitivity assay for human osteosarcoma using tumor xenografts. [2014]